 |
市场调查报告书
商品编码
2008006
肺表面活性剂市场：按类型、药物类型、适应症、给药途径、分销管道和地区划分Pulmonary Surfactant Market, By Type, By Drug Type, By Indications, By Route of Administration, By Distribution Channel, By Geography |
||||||
肺表面活性剂市场预计在2026年达到7.232亿美元，预计到2033年将达到9.478亿美元。预计从2026年到2033年，其复合年增长率将达到7.2%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年： | 2025 | 2026年市场规模： | 7.232亿美元 |
| 历史数据时期： | 2020年至2024年 | 预测期： | 2026年至2033年 |
| 2026年至2033年预测期间的复合年增长率： | 7.20% | 2033年市场规模预测： | 9.478亿美元 |
肺表面活性物质是由脂质和蛋白质组成的复杂物质，富含界面活性剂，存在于覆盖肺泡表面的液体中。表面活性物质在肺的生理功能中发挥着至关重要的作用。其主要生物物理功能是防止肺容量不足时发生肺泡塌陷，并在正常呼吸和用力呼吸期间维持细支气管通畅性。其主要非生物物理和免疫学功能是保护肺部免受吸入颗粒和微生物的损伤和感染。肺表面活性物质在生化组成、形态结构和特定生物物理功能方面具有异质性。界面活性物质可防止肺容量不足时发生肺泡塌陷。
此外，肺表面活性物质也发挥保护肺部免受吸入颗粒和微生物损伤和感染的作用（免疫和非生物物理功能）。肺表面活性物质只能透过肺部灌洗法收集，而这种方法可能会破坏现有的生物物理和生物化学微结构。在解读肺表面活性物质的体外研究结果时，必须始终考虑这些限制。
市场动态
预计在预测期内，多种呼吸道感染疾病和呼吸系统疾病的日益普及将推动全球肺表面活性剂市场的发展。例如，截至2022年5月20日，全球报告的慢性阻塞性肺病（COPD）死亡病例中，90%发生在70岁以下的患者中，主要集中在印度、韩国和孟加拉等中低收入国家。慢性阻塞性肺病是全球主要死因之一，2019年造成323万人死亡。
新疗法核准数量的不断增加是全球肺表面活性剂市场成长的主要驱动力之一。例如，2020年7月，製药公司勃林格殷格翰宣布，欧盟委员会核准尼达尼布用于治疗成人其他慢性纤维化间质性肺部疾病（ILD），这些疾病的表型进行性超出特发性肺纤维化（IPF）。此前，人用药品委员会（CHMP）于2020年5月核准了正面意见。美国食品药物管理局（FDA）、加拿大卫生署和日本药品和医疗设备管理局（PMDA）也已核准尼达尼布用于治疗类似患者族群。此次核准是基于 INBUILD 试验的结果，这是一项随机、双盲、安慰剂对照、平行组 III 期试验，旨在评估尼达尼布治疗进行进行性慢性纤维化间质性肺病 (ILD) 患者的疗效、安全性和耐受性。
本次考试的主要特点。
- 本报告对全球肺表面活性剂市场进行了详细分析，以 2021 年为基准年，给出了预测期（2022-2030 年）的市场规模。
- 本报告指出了各个细分市场的潜在商机，并说明了该市场中具有吸引力的投资提案矩阵。
- 此外，本研究还提供了有关市场驱动因素、限制因素、机会、新药上市和核准、区域前景以及主要企业所采用的竞争策略的关键见解。
- 本报告根据以下参数对全球肺表面活性剂市场的主要企业进行了分析：公司概况、财务业绩、产品系列、地理分布、分销策略、关键发展和策略以及未来计划。
- 透过利用本报告中提出的见解，企业行销负责人和经营团队可以就未来的产品发布、技术升级、市场扩张和行销策略做出明智的决策。
- 本报告面向该产业的各类相关人员，包括投资者、供应商、製造商、经销商、新参与企业和金融分析师。
- 透过各种用于分析全球肺表面活性剂市场的策略矩阵，相关人员将能够更轻鬆地做出决策。
目录
第一章：研究目标与前提条件
- 研究目标
- 前提
- 简称
第二章 市场范围
- 报告摘要
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map（COM）
第三章：市场动态、监管与趋势分析
- 市场动态
- 促进因素
- 阻碍因素
- 市场机会
- 影响分析
- 市场趋势
- 主要进展
- 法规环境
- 产业趋势
- 新产品的核准和上市
- 併购
- PEST分析
第四章 全球肺部表面活性物质市场：依类型划分，2026-2033年
- 概述
- 合成
- 动物源性
第五章 全球肺表面活性剂市场：依药物类型划分，2026-2033年
- 概述
- 乳酸菌 α
- 卢辛坦
- 卡法克坦
第六章 全球肺表面活性剂市场：依适应症划分，2026-2033年
- 概述
- 呼吸窘迫症候群（RDS）
- 呼吸道感染疾病
- 阻塞型肺疾
- 其他（早产儿慢性肺部疾病、肺表面活性蛋白B缺乏症）
第七章 全球肺界面活性剂市场：依给药途径划分，2026-2033年
- 概述
- 气管内给药
- 注射
第八章 全球肺界面活性剂市场：依通路划分，2026-2033年
- 概述
- 医院药房
- 零售药房
- 网路药房
第九章 全球肺表面活性剂市场：依地区划分，2026-2033年
- 北美洲
- 我们
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- ASEAN
- 澳洲
- 韩国
- 亚太其他地区
- 中东
- GCC
- 以色列
- 其他中东国家
- 非洲
- 北非
- 中非
- 南非
第十章 竞争格局
- 热图分析
- 公司简介
- Boehringer Ingelheim
- AbbVie Inc.
- Chiesi Farmaceutici
- ONY Biotech Inc.
- Lyomark Pharma
- Abbott
- Aviva Systems Biology Corporation
- Windtree Therapeutics, Inc
- Tekzima（Noargen）
- Biomatik
- Nanjing Norris Pharm Technology
- Reddot Biotech
第十一章
- 参考
- 调查方法
- 关于本公司
Pulmonary Surfactant Market is estimated to be valued at USD 723.2 Mn in 2026 and is expected to reach USD 947.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 723.2 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.20% | 2033 Value Projection: | USD 947.8 Mn |
Pulmonary surfactant is a complex and highly surface active material composed of lipids and proteins which is found in the fluid lining the alveolar surface of the lungs. Surfactant plays a vital role in pulmonary physiology. It's major biophysical functions is to prevent alveolar collapse at low lung volume and to preserve bronchiolar patency during normal and forced respiration, and it's major non biophysical, immunological, functions is protection of the lungs from injuries and infections caused by inhaled particles and micro-organisms. Pulmonary surfactant is heterogeneous with respect to biochemical composition, morphological organization and specific biophysical functions. Surfactant prevents alveolar collapse at low lung volume, and preserves
bronchiolar patency during normal and forced respiration (biophysical functions). In addition, it is involved in the protection of the lungs from injuries and infections caused by inhaled particles and micro-organisms (immunological, non-biophysical functions). Pulmonary surfactant can only be harvested by lavage procedures, which may disrupt its pre-existing biophysical and biochemical micro-organization. These limitations must always be considered when interpreting ex vivo studies of pulmonary surfactant.
Market Dynamics
Increasing rate of prevalence of several respiratory infection and respiratory is expected to drive the global pulmonary surfactant market over the forecast period. For instance, on May 20, 2022, 90% of COPD (Chronic obstructive pulmonary disease) deaths were reported globally, in those under 70 years of age occur in low- and middle-income countries (LMIC) such as India, Korea and Bangladesh. Chronic obstructive pulmonary disease (COPD) is one of the major cause of death worldwide, causing 3.23 million deaths in 2019.
Increasing drug approvals for novel therapeutic agents are some of the key factors driving the global pulmonary surfactant market growth. For instance, in July 2020, Boehringer Ingelheim, a pharmaceutical company, announced that the European Commission (EC) approved an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF). The approval comes after the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion in May 2020. The U.S. Food and Drug Administration (FDA), Health Canada and the Japan based pharmaceuticals and Medical Devices Agency (PMDA) approved nintedanib as the treatment for the same patient population. The approval is based on the results of INBUILD, which was a randomized, double-blind, placebo-controlled, parallel-group phase III trial, which evaluated the efficacy, safety, and tolerability of nintedanib in patients with chronic fibrosing ILDs with a progressive phenotype.
Key features of the study
- This report provides an in-depth analysis of the global pulmonary surfactant market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global pulmonary surfactant market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
- Key companies covered as a part of this study include, Boehinger Ingelheim, AbbVie Inc, Chiesi Farmaceutici, ONY Biotech Inc., Lyomark Pharma, Abbott, Aviva Systems Biology Corporation, Windtree Therapeutics, Inc, Tekzima (Noargen), Biomatik, Nanjing Norris Pharm Technology, Reddot Biotech
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global pulmonary surfactant market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global pulmonary surfactant
Market Segmentation
- By Type
- Synthetic Pulmonary Surfactant
- Animal Derived Surfactant
- By Drug Type
- Poractant alfa
- Lucinactant
- Calfactant
- By Indications
- Respiratory Distress Syndrome (RDS)
- Respiratory Infections
- Obstructive lung Diseases
- Others (chronic lung disease of prematurity, and surfactant protein-B deficiency)
- By Route of Administration
- Intratracheal
- Injectable
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Regional Insights
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Boehinger Ingelheim
- AbbVie Inc
- Chiesi Farmaceutici
- ONY Biotech Inc.
- Lyomark Pharma
- Abbott
- Aviva Systems Biology Corporation
- Windtree Therapeutics, Inc
- Tekzima (Noargen)
- Biomatik
- Nanjing Norris Pharm Technology
- Reddot Biotech
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Drug Type
- Market Snapshot, By Indications
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Industry Trend
- New Product Approvals/Launch
- Merger and Acquisitions
- PEST Analysis
4. Global Pulmonary Surfactant Market, By Type, 2026 - 2033, (USD Million)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Synthetic Pulmonary Surfactant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Animal Derived Surfactant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
5. Global Pulmonary Surfactant Market, By Drug Type, 2026 - 2033, (USD Million)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Poractant alfa
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Lucinactant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Calfactant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
6. Global Pulmonary Surfactant Market, By Indications, 2026 - 2033, (USD Million)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Respiratory Distress Syndrome (RDS)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Respiratory Infections
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Obstructive lung Diseases
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Others(chronic lung disease of prematurity, and surfactant protein-B deficiency)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
7. Global Pulmonary Surfactant Market, By Route of Administration, 2026 - 2033, (USD Million)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Intratracheal
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Injectable
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
8. Global Pulmonary Surfactant Market, By Distribution Channel, 2026 - 2033, (USD Million)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
9. Global Pulmonary Surfactant Market, By Region, 2026 - 2033, (USD Million)
- Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
- UK
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Heat Map Analysis
- Company Profile
- Boehringer Ingelheim
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Chiesi Farmaceutici
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- ONY Biotech Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Lyomark Pharma
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Abbott
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Aviva Systems Biology Corporation
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Windtree Therapeutics, Inc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Tekzima (Noargen)
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Biomatik
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Nanjing Norris Pharm Technology
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Reddot Biotech
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Analyst Views
11. Section
- References
- Research Methodology
- About Us
界面活性剂市场：依产品、原料、功能及应用划分－2026-2032年全球市场预测界面活性剂提高采收率市场：按类型、来源、技术、分类、功能和应用划分－2026-2032年全球市场预测全球无 PFAS 离子界面活性剂市场（按产品类型、物理形态、应用、分销管道和终端用户行业划分）预测（2026-2032 年）全球无 PFAS 阴离子界面活性剂市场（按最终用途产业、产品类型、应用、形态、通路、原料来源和产业链长度划分）预测（2026-2032 年）全球无 PFAS 非离子界面活性剂市场（按类型、形态、应用和分销管道划分）预测（2026-2032 年）油田水泥防沉剂市场按类型、井型、几何形状、技术、压力等级、应用和终端用户划分，全球预测，2026-2032年溶剂型无 PFAS 界面活性剂市场按功能、产品等级、包装、销售管道和应用划分 - 全球预测，2026-2032 年
界面活性剂市场分析及预测（至2035年）：类型、产品、应用、剂型、材料类型、技术、最终用户、功能、製程、解决方案
界面活性剂：市场占有率分析、产业趋势与统计、成长预测（2026-2031）
2026年全球界面活性剂市场报告